Bayer Hits Par With Patent Suit Over Staxyn Generic

Law360, New York (May 15, 2013, 4:09 PM EDT) -- Bayer Pharma AG on Tuesday hit generic-drug maker Par Pharmaceutical Inc. with a suit in Delaware federal court, accusing its rival of infringing on two patents with a planned generic version of erectile dysfunction treatment Staxyn.

According to Bayer, Par’s abbreviated new drug application for 10-milligram vardenafil hydrochloride orally disintegrating tablets infringes on U.S. Patent Numbers 6,362,178 and 7,696,206, both owned by its unit Bayer Intellectual Property GmbH.

“Unless Par is enjoined from infringing on the [patents], actively inducing infringement of the [patents], and contributing to...
To view the full article, register now.